Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Colman

Showing results (141-150 of 155) with videos related to

Pageof 16
Sort By:
Cancer Causes & Control : CCC|May 13, 2022
Factors associated with changes in exercise behaviors during the COVID-19 pandemicCaroline Himbert, Cassandra A Hathaway, Bailee Daniels, et al.
The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association|March 4, 2022
Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptionsAnita R Peoples, Laura B Oswald, Jennifer Ose, et al.
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Acta Neuropathologica|October 22, 2022
Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1Patrick J Cimino, Courtney Ketchum, Rust Turakulov, et al.
Biomolecules|November 11, 2022
Replicative Instability Drives Cancer ProgressionBenjamin B Morris, Jason P Smith, Qi Zhang, et al.
Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Journal of Behavioral Medicine|February 28, 2024
Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemicElena S Aßmann, Jennifer Ose, Cassandra A Hathaway, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Pageof 16

Showing results (141-150 of 155) with videos related to

Sort By:
Pageof 16
Cancer Causes & Control : CCC|May 13, 2022
Factors associated with changes in exercise behaviors during the COVID-19 pandemicCaroline Himbert, Cassandra A Hathaway, Bailee Daniels, et al.
The Journal of Rural Health : Official Journal of the American Rural Health Association and the National Rural Health Care Association|March 4, 2022
Impact of the COVID-19 pandemic on rural and urban cancer patients' experiences, health behaviors, and perceptionsAnita R Peoples, Laura B Oswald, Jennifer Ose, et al.
Science Translational Medicine|March 11, 2021
A first-in-human phase 0 clinical study of RNA interference-based spherical nucleic acids in patients with recurrent glioblastomaPriya Kumthekar, Caroline H Ko, Tatjana Paunesku, et al.
Acta Neuropathologica|October 22, 2022
Expanded analysis of high-grade astrocytoma with piloid features identifies an epigenetically and clinically distinct subtype associated with neurofibromatosis type 1Patrick J Cimino, Courtney Ketchum, Rust Turakulov, et al.
Biomolecules|November 11, 2022
Replicative Instability Drives Cancer ProgressionBenjamin B Morris, Jason P Smith, Qi Zhang, et al.
Nature Medicine|February 12, 2019
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastomaTimothy F Cloughesy, Aaron Y Mochizuki, Joey R Orpilla, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Medicine|May 15, 2023
Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Journal of Behavioral Medicine|February 28, 2024
Risk factors and health behaviors associated with loneliness among cancer survivors during the COVID-19 pandemicElena S Aßmann, Jennifer Ose, Cassandra A Hathaway, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Pageof 16